The hypotensive effect of fresh, lypholised plasma, both during, and after cardiopulmonary bypass is demonstrated. It is postulated that the mediator is bradykinin, or one of it precursors.
References
1.
BlandJ. H. L., LaverM. B., LowensteinE. (1973): “Vasodilator Effect of Commercial E. Plasma Protein Fraction Solutions”, J. Amer. Med. Ass., 224, 1721.
2.
FerreiraS. H., VaneJ. R. (1967a): “The Disappearance of Bradykinin and Eledoisin in the Circulation and Vascular Beds of the Cat”, Brit. J. Pharmacol, 30, 417.
3.
FerreiraS. H., VaneJ. R. (1967b): “Half Lives of Peptides and Amines in the Circulation”, Nature (Lond.), 215, 1237.
4.
IzakaK., TsutsuiE., MimaY., HasegawaE. (1974): “A Bradykinin Like Substance in Heat Treated Human Plasma Protein Solution”, Transfusion (Philad)., 14, 242.
5.
MackayM., MaycockW. d'A., SilkE., CombridgeB. S. (1965): “Studies on Fibrinogen Fractions Isolated from Human Plasma by Precipitation with Cold Ether”, Brit. J. Haemat., 11, 563.
6.
MaycockW. d'A., EvansS., ValletL., CombridgeB., WolfP., McGibbonN., FrenchE. E., WalletL. H., DacieJ. V., BiggsR., HandleyD., MacfarlaneR. G. (1963): “Further Experience with a Concentrate Containing Human Antihaemophilic Factor”, Brit. J. Haemat., 9, 215.
7.
RyanJ. W., RobleroJ., StewartJ. M. (1968): “Inactivation of Bradykinin in the Pulmonary Circulation”, Biochem. J., 110, 795.
8.
TordaT. A., HarrisonG. A., McCullochC. H., WrightJ. S., StaceyR., RobertsonM. (1973): “Circulatory Effects of Stable Plasma Protein Solution”, Med. J. Aust., 1, 798.
9.
VaneJ. R. (1969): “The Release and Fate of Vasoactive Hormones in the Circulation”, Brit. J. Pharmacol., 35, 209.
